There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.

At the same time, the proportion of people using the drugs to control type 2 diabetes has declined Semaglutide is being used disproportionately by females, whites and people with obesity TUESDAY ...

TUESDAY, July 23, 2024 (HealthDay News) -- The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 ...

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is changing how Americans eat, with implications already visible in the food and beverage industry. A new study from ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

Study shows shift in GLP-1 drug use for obesity, not diabetes. Dennis Thompson, HealthDay News. Tue, July 23, 2024 at 5:58 PM UTC. 2 min read.